Article citationsMore>>

Kim, K.R., Ko, G.Y., Sung, K.B., Yoon, H.K., Shin, J.H., Song, H.Y., Ryu, J.H., Hwang, S., Lee, S.G. and Yu, E. (2008) Transjugular Liver Biopsy in Patients with Living Donor Liver Transplantation: Comparison with Percutaneous Biopsy. Liver Transplantation, 14, 971-979.
http://dx.doi.org/10.1002/lt.21448

has been cited by the following article:

• TITLE: A Study on the Safety of Liver Biopsy Inpatients with Von Willebrand’s Disease

  AUTHORS: Patrick P. Basu, Niraj J. Shah, Mark M. Aloysius, K. Rayapudi, Robert Brown

  KEYWORDS: Liver Biopsy, vW Disease, Safety, Complications

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.5 No.9, September 24, 2015

  ABSTRACT: Objectives: Liver biopsy remains the gold standard for diagnosis of chronic liver diseases. Outpatient percutaneous biopsy is generally safe with a mortality rate of 0.17% and hospitalization rate for bleeding of 3%. Von Willebrand disease (vWD) syndrome is the most common inherited hematological disorder with a prevalence of 1% - 3% globally. We sought to study whether vWD increases the risk of bleeding for liver biopsies. Methods: All patients (n = 120) who underwent outpatient percutaneous liver biopsies from 1997 to 2007 were analyzed. Demographics, PT/INR, platelet count, vW antigen and ristocetin induced platelet aggregation were studied. Results: No vWD patients had major bleeding that required transfusion, hospitalization or surgery but 9 (75%) had minor local bleeding and all had ecchymosis, which resolved spontaneously within 24 hours. Conclusions: Patients with vW factor deficiency can undergo percutaneous liver biopsy without major bleeding. Minor bleeding may occur at a slightly higher rate. vWD is not a contraindication to percutaneous liver biopsy.